Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
The typical compounded dose range (250 to 500 mcg subcutaneously once daily) is based on empirical clinical practice, not Phase I dose-finding trials
Weigh yourself once weekly at the same time of day (ideally first thing in the morning after voiding) wearing similar clothing to ensure consistency and accurately track treatment response
Our guide to the difference between tirzepatide and retatrutide covers how the addition of glucagon receptor agonism changes the metabolic and longevity profile
These preclinical findings support clinical trial results showing that tirzepatide, a dual GIPR/GLP-1R agonist, exhibits greater anti-obesity effects than GLP-1 receptor agonists alone
People with MEN2A or MEN2B should avoid GLP-1 drugs entirely
